


FDA adds warning to Ozempic label about risk for blocked intestines

September 28 2023, by Cara Murez



Ozempic, a type 2 diabetes drug that has increasingly been used to help



with weight loss, will now be labeled as having the potential to block intestines.

The U.S. Food and Drug Administration recently made the <u>label update</u> for the drug made by Novo Nordisk, without directly citing Ozempic as the cause for this condition.

"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure," the label reads.

The side effect, known by the medical term "ileus," is also listed on labels for the <u>weight-loss</u> drug <u>Wegovy</u>, also made by Novo Nordisk, and in the diabetes medication <u>Mounjaro</u>, made by Eli Lilly, *CBS News* reported.

Both Ozempic and Wegovy are known generically as semaglutide. Among more than 8,500 reports of gastrointestinal disorders after using semaglutide medications through June 30, ileus is mentioned in 33 cases, including two deaths, *CBS News* reported.

The two <u>pharmaceutical companies</u> that make these medications are both being sued for claims that the drugs can cause a similar health issue known as gastroparesis, or stomach paralysis, *CBS News* reported.

More information: The U.S. National Library of Medicine has more on <u>ileus</u>.

Copyright © 2023 HealthDay. All rights reserved.

Citation: FDA adds warning to Ozempic label about risk for blocked intestines (2023, September



28) retrieved 13 May 2024 from https://medicalxpress.com/news/2023-09-fda-ozempic-blocked-intestines.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.